Kairos Pharma, Ltd.
KAPA
$1.20
-$0.03-2.44%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.19% | -39.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.01% | -12.45% | |||
| Operating Income | -15.01% | 12.45% | |||
| Income Before Tax | -12.68% | -28.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.68% | -28.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.68% | -28.78% | |||
| EBIT | -15.01% | 12.45% | |||
| EBITDA | -15.50% | 12.80% | |||
| EPS Basic | -3.90% | -8.61% | |||
| Normalized Basic EPS | -3.82% | 32.56% | |||
| EPS Diluted | -3.90% | -8.61% | |||
| Normalized Diluted EPS | -3.82% | 32.56% | |||
| Average Basic Shares Outstanding | 8.42% | 18.59% | |||
| Average Diluted Shares Outstanding | 8.42% | 18.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||